ECSP034480A - PIRAZOL DERIVATIVES - Google Patents
PIRAZOL DERIVATIVESInfo
- Publication number
- ECSP034480A ECSP034480A EC2003004480A ECSP034480A ECSP034480A EC SP034480 A ECSP034480 A EC SP034480A EC 2003004480 A EC2003004480 A EC 2003004480A EC SP034480 A ECSP034480 A EC SP034480A EC SP034480 A ECSP034480 A EC SP034480A
- Authority
- EC
- Ecuador
- Prior art keywords
- formula
- compounds
- syndrome
- pharmaceutical compositions
- conditions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/40—Acylated on said nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Reproductive Health (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Gynecology & Obstetrics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La invención proporciona compuestos de la fórmula I donde R1, R2, R3, R4 son como se definen y sus sales farmacéuticamente aceptables. Se indica que los compuestos de la fórmula 1 tienen actividad para inhibir las cdk5, cdk2 y GSK-3. Proporciona composiciones farmacéuticos y métodos que comprenden compuestos de la fórmula 1 para tratar y prevenir enfermedades y condiciones que implican crecimiento celular anormal, tales como el cáncer, enfermedades y condiciones neurodegenerativas y las afectadas por la neurotrasmisión de la dopamina. También se describen composiciones farmacéuticas y métodos que comprenden compuestos de fórmula 1 para tratar la fertilidad masculina y la motilidad espermática, diabetes mellitus, deterioro de la tolerancia a la glucosa, síndrome metabólico o síndrome X ; síndrome de poliquistosis ovárica, adipogénesis y obesidad; miogénesis y fragilidad, por ejemplo el deterioro de las características físicas relacionado com. la edad ; sarcopenia aguda, por ejemplo atrofia muscular y/o caquexia asociada con las quemaduras, reposo en cama, inmovilización de miembros o importante cirugía toráxico, abdominal, y/o ortopédica; sepsis; caída del cabello, raro y calvicie; e inmunodeficiencia.The invention provides compounds of the formula I wherein R1, R2, R3, R4 are as defined and their pharmaceutically acceptable salts. The compounds of formula 1 are indicated to have activity to inhibit cdk5, cdk2 and GSK-3. It provides pharmaceutical compositions and methods comprising compounds of the formula 1 for treating and preventing diseases and conditions that involve abnormal cell growth, such as cancer, neurodegenerative diseases and conditions and those affected by the neurotransmission of dopamine. Pharmaceutical compositions and methods comprising compounds of formula 1 for treating male fertility and sperm motility, diabetes mellitus, impaired glucose tolerance, metabolic syndrome or syndrome X are also described; polycystic ovarian syndrome, adipogenesis and obesity; myogenesis and fragility, for example the deterioration of physical characteristics related to com. age ; acute sarcopenia, for example muscular atrophy and / or cachexia associated with burns, bed rest, limb immobilization or major thoracic, abdominal, and / or orthopedic surgery; sepsis; hair loss, rare and baldness; and immunodeficiency.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22941500P | 2000-08-31 | 2000-08-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP034480A true ECSP034480A (en) | 2003-03-31 |
Family
ID=22861151
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2003004480A ECSP034480A (en) | 2000-08-31 | 2003-02-17 | PIRAZOL DERIVATIVES |
Country Status (39)
| Country | Link |
|---|---|
| EP (1) | EP1313710A1 (en) |
| JP (1) | JP2004507526A (en) |
| KR (1) | KR20030027093A (en) |
| CN (1) | CN1518543A (en) |
| AP (1) | AP2001002266A0 (en) |
| AR (1) | AR035345A1 (en) |
| AU (1) | AU2001280009A1 (en) |
| BG (1) | BG107455A (en) |
| BR (1) | BR0113574A (en) |
| CA (1) | CA2420363A1 (en) |
| CR (1) | CR6881A (en) |
| CZ (1) | CZ2003468A3 (en) |
| DO (1) | DOP2001000243A (en) |
| DZ (1) | DZ3398A1 (en) |
| EA (1) | EA200300205A1 (en) |
| EC (1) | ECSP034480A (en) |
| EE (1) | EE200300085A (en) |
| GT (1) | GT200100179A (en) |
| HN (1) | HN2001000192A (en) |
| HR (1) | HRP20030140A2 (en) |
| HU (1) | HUP0302669A3 (en) |
| IL (1) | IL154016A0 (en) |
| IS (1) | IS6687A (en) |
| MA (1) | MA26946A1 (en) |
| MX (1) | MXPA03001785A (en) |
| NO (1) | NO20030958D0 (en) |
| NZ (1) | NZ523656A (en) |
| OA (1) | OA12368A (en) |
| PA (1) | PA8528101A1 (en) |
| PE (1) | PE20020470A1 (en) |
| PL (1) | PL360742A1 (en) |
| PY (1) | PY0121331A (en) |
| SK (1) | SK2002003A3 (en) |
| SV (1) | SV2002000618A (en) |
| TN (1) | TNSN01132A1 (en) |
| UY (1) | UY26909A1 (en) |
| WO (1) | WO2002018346A1 (en) |
| YU (1) | YU14703A (en) |
| ZA (1) | ZA200301064B (en) |
Families Citing this family (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2298311B1 (en) | 1999-01-13 | 2012-05-09 | Bayer HealthCare LLC | w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors |
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| US7351834B1 (en) | 1999-01-13 | 2008-04-01 | Bayer Pharmaceuticals Corporation | ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| AU2001290912A1 (en) | 2000-09-15 | 2002-03-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US7473691B2 (en) | 2000-09-15 | 2009-01-06 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US6660731B2 (en) | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US6610677B2 (en) | 2000-09-15 | 2003-08-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US6613776B2 (en) | 2000-09-15 | 2003-09-02 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| BR0116493A (en) | 2000-12-21 | 2003-09-30 | Vertex Pharma | Pyrazole compounds useful as protein kinase inhibitors |
| PT1441724E (en) * | 2001-09-27 | 2007-10-15 | Serono Lab | Methods of increasing endogenous testosterone levels |
| DK1478358T3 (en) | 2002-02-11 | 2013-10-07 | Bayer Healthcare Llc | Sorafenibtosylate for the treatment of diseases characterized by abnormal angiogenesis |
| WO2003068229A1 (en) | 2002-02-11 | 2003-08-21 | Bayer Pharmaceuticals Corporation | Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors |
| MY141867A (en) | 2002-06-20 | 2010-07-16 | Vertex Pharma | Substituted pyrimidines useful as protein kinase inhibitors |
| WO2004007504A1 (en) * | 2002-07-17 | 2004-01-22 | Pharmacia Italia S.P.A. | Heterobicyclic pyrazole derivatives as kinase inhibitors |
| MXPA05001367A (en) | 2002-08-02 | 2005-04-28 | Vertex Pharma | Pyrazole compositions useful as inhibitors of gsk-3. |
| JP2006504725A (en) | 2002-10-09 | 2006-02-09 | ファイザー・プロダクツ・インク | Pyrazole compounds for the treatment of neurodegenerative disorders |
| WO2004035588A1 (en) * | 2002-10-15 | 2004-04-29 | Smithkline Beecham Corporation | Pyradazine compounds as gsk-3 inhibitors |
| EP1597234B1 (en) * | 2003-02-27 | 2008-10-08 | Smithkline Beecham Corporation | Novel compounds |
| EP1636585B2 (en) | 2003-05-20 | 2012-06-13 | Bayer HealthCare LLC | Diaryl ureas with kinase inhibiting activity |
| AU2004258841B8 (en) * | 2003-06-05 | 2010-01-07 | Elan Pharmaceuticals, Inc. | Acylated amino acid amidyl pyrazoles and related compounds |
| EP2256106B1 (en) * | 2003-07-22 | 2015-05-06 | Astex Therapeutics Limited | 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators |
| GB0317127D0 (en) * | 2003-07-22 | 2003-08-27 | Astex Technology Ltd | Pharmaceutical compounds |
| PL1663978T3 (en) | 2003-07-23 | 2008-04-30 | Bayer Healthcare Llc | Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
| JP2006528661A (en) * | 2003-07-25 | 2006-12-21 | ファイザー・インク | Aminopyrazole compounds and use as CHK1 inhibitors |
| CA2547283C (en) * | 2003-11-26 | 2010-11-09 | Pfizer Products Inc. | Aminopyrazole derivatives as gsk-3 inhibitors |
| JP5138938B2 (en) | 2003-12-19 | 2013-02-06 | プレキシコン インコーポレーテッド | Compounds and methods for the development of RET modulators |
| US7244757B2 (en) * | 2004-04-01 | 2007-07-17 | Pfizer Inc | Pyrazole-amine compounds for the treatment of neurodegenerative disorders |
| EP1742921A2 (en) * | 2004-04-21 | 2007-01-17 | AstraZeneca AB | Pyrazole derivatives useful for the treatment of cancer |
| US7838524B2 (en) | 2004-04-30 | 2010-11-23 | Bayer Healthcare Llc | Substituted pyrazolyl urea derivatives useful in the treatment of cancer |
| US7498342B2 (en) | 2004-06-17 | 2009-03-03 | Plexxikon, Inc. | Compounds modulating c-kit activity |
| WO2006004865A1 (en) * | 2004-06-29 | 2006-01-12 | Rigel Pharmaceuticals, Inc. | 2-substituted quinoline compounds and their uses as inhibitors of the ige receptor signaling cascade |
| US7491720B2 (en) | 2004-10-29 | 2009-02-17 | Banyu Pharmaceutical Co., Ltd. | Aminopyridine derivatives having Aurora A selective inhibitory action |
| MX2007005857A (en) | 2004-11-17 | 2007-10-10 | Mikana Therapeutics Inc | Kinase inhibitors. |
| AR054425A1 (en) | 2005-01-21 | 2007-06-27 | Astex Therapeutics Ltd | PIPERIDIN ADDITION SALTS 4-IL-ACID AMID 4- (2,6-DICLORO-BENZOILAMINO) 1H-PIRAZOL-3-CARBOXILICO. |
| US8404718B2 (en) | 2005-01-21 | 2013-03-26 | Astex Therapeutics Limited | Combinations of pyrazole kinase inhibitors |
| DK2383268T3 (en) | 2005-02-04 | 2015-09-14 | Astrazeneca Ab | PYRAZOLYLAMINOPYRIDINDERIVATER useful as kinase inhibitors |
| EP1847531A4 (en) * | 2005-02-09 | 2009-04-22 | Takeda Pharmaceutical | Pyrazole compound |
| KR101362621B1 (en) | 2005-02-16 | 2014-02-13 | 아스트라제네카 아베 | Chemical compouns |
| CA2608009A1 (en) | 2005-05-16 | 2006-11-23 | Astrazeneca Ab | Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors |
| EP1741708A1 (en) | 2005-06-28 | 2007-01-10 | Sanofi-Aventis Deutschland GmbH | Heteroaryl-substituted amides comprising an unsaturated or cyclic linker group, and their use as pharmaceuticals |
| EP2275096A3 (en) | 2005-08-26 | 2011-07-13 | Braincells, Inc. | Neurogenesis via modulation of the muscarinic receptors |
| EP2258357A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
| BRPI0616630B8 (en) | 2005-09-30 | 2021-05-25 | Miikana Therapeutics Inc | substituted pyrazole compounds |
| WO2007047978A2 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
| BRPI0618011A2 (en) | 2005-10-28 | 2011-08-16 | Astrazeneca Ab | compound or a pharmaceutically acceptable salt thereof, process for the preparation thereof, pharmaceutical composition, use of a compound or a pharmaceutically acceptable salt thereof, and methods for producing an antiproliferative effect and a pro-apoptotic effect in an animal warm-blooded to treat disease and to produce a jak inhibiting effect on a warm-blooded animal |
| EP2314289A1 (en) | 2005-10-31 | 2011-04-27 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| JP5249770B2 (en) | 2005-11-03 | 2013-07-31 | バーテックス ファーマシューティカルズ インコーポレイテッド | Aminopyridines useful as kinase inhibitors |
| US7572809B2 (en) * | 2005-12-19 | 2009-08-11 | Hoffmann-La Roche Inc. | Isoquinoline aminopyrazole derivatives |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| EP2021000A2 (en) | 2006-05-09 | 2009-02-11 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| DK2086642T3 (en) * | 2006-10-18 | 2014-09-29 | Periness Ltd | DNASE FOR TREATMENT OF SUBFERTILITY BY MEN |
| WO2008046919A2 (en) * | 2006-10-21 | 2008-04-24 | Abbott Gmbh & Co. Kg | Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors |
| WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
| US7737149B2 (en) * | 2006-12-21 | 2010-06-15 | Astrazeneca Ab | N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof |
| US8093268B2 (en) | 2007-01-24 | 2012-01-10 | Glaxo Group Limited | Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2S-phenylpiperidin-3S-yl-) |
| JP2010533729A (en) | 2007-07-17 | 2010-10-28 | プレキシコン，インコーポレーテッド | Compounds and methods for kinase regulation, and adaptations therefor |
| WO2009017453A1 (en) * | 2007-07-30 | 2009-02-05 | Astrazeneca Ab | New therapeutic combination of an antipsychotic and a gsk3 inhibitor 958 |
| EA019104B1 (en) | 2007-09-21 | 2014-01-30 | Эррей Биофарма Инк. | Glucokinase activators |
| JPWO2009130900A1 (en) * | 2008-04-24 | 2011-08-11 | 日本曹達株式会社 | Oxime derivatives, intermediate compounds and plant disease control agents |
| US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| CA2738573C (en) | 2009-04-03 | 2013-02-19 | F. Hoffmann-La Roche Ag | Compositions of propane-1 sulfonic acid {3-[5-(4-chloro-phenyl)-1h-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide and uses thereof |
| JP2013506691A (en) * | 2009-10-02 | 2013-02-28 | バーテックス ファーマシューティカルズ インコーポレイテッド | Pyrazole inhibitors of phosphatidylinositol 3-kinase |
| JP2013510166A (en) | 2009-11-06 | 2013-03-21 | プレキシコン インコーポレーテッド | Compounds, methods and applications for kinase regulation |
| US9266855B2 (en) | 2010-09-27 | 2016-02-23 | AbbVie Deutschland GmbH & Co. KG | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
| US9090592B2 (en) | 2010-12-30 | 2015-07-28 | AbbVie Deutschland GmbH & Co. KG | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
| PE20141360A1 (en) | 2011-02-07 | 2014-10-13 | Plexxikon Inc | COMPOUNDS AND METHODS FOR THE MODULATION OF KINASES AND INDICATIONS FOR THEM. |
| TWI558702B (en) | 2011-02-21 | 2016-11-21 | 普雷辛肯公司 | Solid forms of a pharmaceutically active substance |
| US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
| RU2016109243A (en) | 2013-08-16 | 2017-09-20 | Мерк Патент Гмбх | 3-SUBSTITUTED CYCLOPENTHYLAMINE DERIVATIVES |
| CN106580986B (en) * | 2016-11-28 | 2017-09-15 | 王保亮 | A kind of pharmaceutical composition for treating teen bra |
| TW202043205A (en) | 2018-12-31 | 2020-12-01 | 美商拜歐米富士恩有限公司 | Inhibitors of menin-mll interaction |
| WO2020142557A1 (en) | 2018-12-31 | 2020-07-09 | Biomea Fusion, Llc | Irreversible inhibitors of menin-mll interaction |
| CA3128155C (en) * | 2019-01-31 | 2023-09-19 | Pfizer Inc. | 3-carbonylamino-5-cyclopentyl-1h-pyrazole compounds having inhibitory activity on cdk2 |
| US12479816B2 (en) | 2019-02-08 | 2025-11-25 | University of Pittsburgh—of the Commonwealth System of Higher Education | 20-HETE formation inhibitors |
| US20240132485A1 (en) * | 2020-10-16 | 2024-04-25 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof |
| TW202229268A (en) * | 2020-12-22 | 2022-08-01 | 大陸商上海拓界生物醫藥科技有限公司 | Cdk2 inhibitor and preparation method thereof |
| CA3217792A1 (en) | 2021-05-07 | 2022-11-10 | Kymera Therapeutics, Inc | Cdk2 degraders and uses thereof |
| EP4347582A4 (en) * | 2021-05-27 | 2025-05-07 | Boundless Bio, Inc. | CHECKPOINT KINASE 1 (CHK1) INHIBITORS AND THEIR USES |
| WO2022266190A1 (en) | 2021-06-16 | 2022-12-22 | Blueprint Medicines Corporation | Substituted pyrimidinyl-pyrazoles as cdk2 inhibitors |
| CN117897384A (en) | 2021-06-28 | 2024-04-16 | 缆图药品公司 | CDK2 inhibitors |
| TW202317564A (en) * | 2021-07-01 | 2023-05-01 | 大陸商上海拓界生物醫藥科技有限公司 | Cdk2 inhibitor, a preparation method and a use thereof |
| JP7891524B2 (en) | 2021-08-11 | 2026-07-16 | バイオメア フュージョン，インコーポレイテッド | Covalent inhibitors of menin-MLL interaction in diabetes mellitus |
| MX2024002189A (en) | 2021-08-20 | 2024-06-11 | Biomea Fusion Inc | Crystalline form of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyri midin-6-yl]phenyl]-4-[[3(r)-[(1-oxo -2-propen-1-yl)amino]-1-piper idinyl]methyl]-2-pyridinecarboxamide, an irreversible menin-mll inhibitor for the treatment of cancer. |
| TW202325280A (en) * | 2021-11-09 | 2023-07-01 | 大陸商上海拓界生物醫藥科技有限公司 | An aminopyrazole derivative, preparation method and use thereof |
| WO2023092088A1 (en) * | 2021-11-19 | 2023-05-25 | Blueprint Medicines Corporation | Cdk2 inhibitors and methods of making and using same |
| WO2023239629A1 (en) * | 2022-06-06 | 2023-12-14 | Plexium, Inc. | Compounds and pharmaceutical compositions that degrade cdk2 |
| WO2024155719A1 (en) | 2023-01-18 | 2024-07-25 | Biomea Fusion, Inc. | Crystalline forms of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(l-oxo-2-propen-l-yl)amino]-l-piperidinyl]methyl]-2- pyridinecarboxamide as a covalentinhibitor of menin-mll interaction |
| WO2026024674A1 (en) | 2024-07-22 | 2026-01-29 | Genesis Therapeutics, Inc. | Methods of treating skp2-associated cancers |
| TW202613099A (en) * | 2024-08-08 | 2026-04-01 | 大陸商上海美悅生物科技發展有限公司 | Substituted phenyl compounds, pharmaceutical compositions and uses thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4437270B2 (en) * | 1997-12-22 | 2010-03-24 | バイエル コーポレイション | Inhibition of RAF kinase using substituted heterocyclic ureas |
| KR100579792B1 (en) * | 1998-05-13 | 2006-05-12 | 동화약품공업주식회사 | New 2,5-pyridinedicarboxylic acid derivatives |
| GB9811427D0 (en) * | 1998-05-29 | 1998-07-22 | Zeneca Ltd | Chemical compounds |
| EP1199306B1 (en) * | 1999-07-26 | 2005-12-07 | Banyu Pharmaceutical Co., Ltd. | Biarylurea derivatives |
| US6387900B1 (en) * | 1999-08-12 | 2002-05-14 | Pharmacia & Upjohn S.P.A. | 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents |
| MXPA02001498A (en) * | 1999-08-12 | 2003-07-21 | Pharmacia & Italia S P A | 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents. |
| BR0015995A (en) * | 1999-11-30 | 2002-08-06 | Pfizer Prod Inc | 2,4-diaminopyrimidine compounds useful as immunosuppressants |
| BR0110302A (en) * | 2000-04-18 | 2003-01-14 | Agouron Pharma | Pyrazole compounds for protein kinase inhibition, pharmaceutically acceptable salt and prodrug, pharmaceutically active metabolite or pharmaceutically acceptable salt of metabolite, pharmaceutical composition, method of treating disease in mammals mediated by protein kinase activity, modulation or inhibition method of the activity of a protein kinase receptor |
-
2001
- 2001-08-24 DZ DZ013398A patent/DZ3398A1/en active
- 2001-08-24 AP APAP/P/2001/002266A patent/AP2001002266A0/en unknown
- 2001-08-24 OA OA1200300050A patent/OA12368A/en unknown
- 2001-08-24 PL PL36074201A patent/PL360742A1/en not_active Application Discontinuation
- 2001-08-24 BR BR0113574-0A patent/BR0113574A/en not_active IP Right Cessation
- 2001-08-24 YU YU14703A patent/YU14703A/en unknown
- 2001-08-24 CA CA002420363A patent/CA2420363A1/en not_active Abandoned
- 2001-08-24 KR KR10-2003-7002894A patent/KR20030027093A/en not_active Ceased
- 2001-08-24 NZ NZ523656A patent/NZ523656A/en unknown
- 2001-08-24 AU AU2001280009A patent/AU2001280009A1/en not_active Abandoned
- 2001-08-24 HR HR20030140A patent/HRP20030140A2/en not_active Application Discontinuation
- 2001-08-24 CZ CZ2003468A patent/CZ2003468A3/en unknown
- 2001-08-24 MX MXPA03001785A patent/MXPA03001785A/en not_active Application Discontinuation
- 2001-08-24 CN CNA018147615A patent/CN1518543A/en active Pending
- 2001-08-24 EP EP01958287A patent/EP1313710A1/en not_active Withdrawn
- 2001-08-24 IL IL15401601A patent/IL154016A0/en unknown
- 2001-08-24 EA EA200300205A patent/EA200300205A1/en unknown
- 2001-08-24 JP JP2002523464A patent/JP2004507526A/en active Pending
- 2001-08-24 HU HU0302669A patent/HUP0302669A3/en unknown
- 2001-08-24 WO PCT/IB2001/001540 patent/WO2002018346A1/en not_active Ceased
- 2001-08-24 SK SK200-2003A patent/SK2002003A3/en not_active Application Discontinuation
- 2001-08-24 EE EEP200300085A patent/EE200300085A/en unknown
- 2001-08-27 PY PY200100121331A patent/PY0121331A/en unknown
- 2001-08-27 UY UY26909A patent/UY26909A1/en not_active Application Discontinuation
- 2001-08-28 HN HN2001000192A patent/HN2001000192A/en unknown
- 2001-08-29 PE PE2001000872A patent/PE20020470A1/en not_active Application Discontinuation
- 2001-08-29 DO DO2001000243A patent/DOP2001000243A/en unknown
- 2001-08-29 AR ARP010104115A patent/AR035345A1/en unknown
- 2001-08-30 SV SV2001000618A patent/SV2002000618A/en unknown
- 2001-08-30 TN TNTNSN01132A patent/TNSN01132A1/en unknown
- 2001-08-30 GT GT200100179A patent/GT200100179A/en unknown
- 2001-08-31 PA PA20018528101A patent/PA8528101A1/en unknown
-
2003
- 2003-01-13 BG BG107455A patent/BG107455A/en unknown
- 2003-01-15 CR CR6881A patent/CR6881A/en not_active Application Discontinuation
- 2003-01-16 IS IS6687A patent/IS6687A/en unknown
- 2003-02-07 ZA ZA200301064A patent/ZA200301064B/en unknown
- 2003-02-17 EC EC2003004480A patent/ECSP034480A/en unknown
- 2003-02-21 MA MA27050A patent/MA26946A1/en unknown
- 2003-02-28 NO NO20030958A patent/NO20030958D0/en not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2001000243A (en) | PIRAZOL DERIVATIVES | |
| ECSP034445A (en) | IMIDAZOL DERIVATIVES | |
| BR0201691A (en) | Thiazole Derivatives | |
| NO20064412L (en) | Condensed heterocycle derivative, medical composition containing the same and medical use thereof | |
| ECSP23077322A (en) | PHOSPHORUS DERIVATIVES AS NEW SOS1 INHIBITORS | |
| PA8593101A1 (en) | COMPOSITIONS FOR THE TREATMENT OF ABNORMAL CELL GROWTH | |
| NO20081844L (en) | Therapeutic compounds | |
| UY28489A1 (en) | GLUCOPIRANOSILOXI-PIRAZOLES, MEDICATIONS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCEDURE FOR THEIR PREPARATION | |
| NO20055421L (en) | Quinoline derivatives as phosphodiesterase inhibitors | |
| NO20055680L (en) | Hexahydropyridoisoquinolines as DPP-IV inhibitors | |
| DOP2006000169A (en) | BETA-SECRETASE SPIROPIPERIDINE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | |
| NO20072389L (en) | Substituted benzoquinoline derivatives | |
| BRPI0514692A (en) | sigma receptor inhibitors | |
| CR8147A (en) | PIRIDO DERIVATIVES 2, 1A-ISOQUINOLINE, AS DPP-IV INHIBITORS | |
| ECSP055685A (en) | NEW COMPOUNDS OF ISOTIAZOL AND ISOXAZOL AS INHIBITORS OF THE TRANSFORMING GROWTH FACTOR (TGF) | |
| ECSP045156A (en) | INDOLILALQUILAMINE DERIVATIVES AS LIGANDOS 5-HIDROXITRIPTAMINA-6 | |
| MY135850A (en) | Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use | |
| AR044200A1 (en) | COMPOSITION OF FONDAPARINUX SODICO DE HIGH PURITY, A PROCEDURE FOR THE PREPARATION OF THIS COMPOSITION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT AS AN ACTIVE PRINCIPLE | |
| AR029420A1 (en) | DERIVATIVES OF PIPERIDINILOXI AND PIRROLIDINILOXI OXAZOLIDINONA, A PROCEDURE FOR THE PREPARATION, INTERMEDIARIES AND THE USE OF SUCH DERIVATIVES FOR THE MANUFACTURE OF AN ANTIBACTERIAL MEDICINAL PRODUCT | |
| BRPI0411661A (en) | n-phenylpiperazine derivatives and methods of prophylaxis or treatment of 5ht 2c receptor-associated diseases | |
| DK1124841T3 (en) | Substituted phenylalkenoylguanidines, processes for their preparation, use thereof as drugs or diagnostics and drugs containing them | |
| AR044712A1 (en) | DERIVATIVES OF INDOL, PROCEDURES FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR EMPLOYMENT IN THE MANUFACTURE OF MEDICINES. | |
| DOP2002000519A (en) | PROCEDURE FOR THE PREPARATION OF SUBSTITUTED BICYCLE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELLULAR GROWTH | |
| PT1157015E (en) | USE OF POLYCYCLIC 2-AMINO-TRIAZOLE SYSTEMS FOR THE PREPARATION OF MEDICINES FOR THE TREATMENT OF LIPOMETABOLIC PERTURBACOES, OBESITY AND TYPE II DIABETES | |
| TW200505892A (en) | Substituted 3-(benzoylureido)thiophene derivatives, processes for preparing them and their use |